Joint Meeting 2020 · In addition to the poster in the poster exhibition, some of the posters have...

Joint Meeting 2020Swiss Society for Infectious Diseases SSISwiss Society for Hospital Hygiene SSHH

September 2-4, 2020Palexpo Congress Centre, Le Grand-Saconnex, Geneva

PROGRAM © Genève Tourisme

Schweizerische Gesellschaft für InfektiologieSwiss Society for Infectious DiseasesSociété Suisse d’Infectiologie

Organizing SocietiesProf. Nicolas Müller, University Hospital of ZurichPresident SSIDr med. Matthias Schlegel, Kantonsspital St.GallenPresident SSHH

Congress offi ce ManagementMeeting.com Congress OrganisationRue des Pâquis 1 • CH-1033 Cheseaux-sur-Lausannewww.meeting-com.ch • [email protected] • T 021 312 92 61

WEARING A MASK IS COMPULSORY

2 3

Welcome word 5

General information 6-9

Joint meeting organization 10

Program at a glance 11-13

Program 02.09.20 16-18

Program 03.09.20 19-23

Program 04.09.19 24-26

Sponsors 27-28Tabl

e of

con

tent

4 54 5

Dear members of the SSHH,Dear members of the SSI,

We are pleased to inform you that we are continuing to plan this year’s annual meeting in Geneva from 2 to 4 September ! Given the current situation, it seems realistic to us that it could take place this year.

We are very happy about it! We believe that, especially in these times, analysing what has happened and preparing for the future with a common event and personal exchange is particularly important !

However, there are several changes : the congress will take place without the participation of the Swiss Society of Microbiology. This results in changes to the programme, which we totally reworked. The aim was to remove some parts of the previous programme, and to insert thematic blocks on COVID-19. We hope to be able to offer you an even more exciting program !

A safety concept is in place and there is enough space to adhere to all mesaures. Also, wearing a mask is compulsory.

We hope that the situation will remain stable and we look forward to seeing you in Geneva !

On behalf of the Committee, we send you our warmest greetings

Nicolas Müller Matthias SchlegelPresident SSI President SGSHW

elco

me

to G

enev

a

6 7

Information for speakersThe lecture rooms are equipped with laptop and beamers.We ask the speakers to save their presentation on a USB drive and deliver it to the to the organizers in good time in the conference room, at latest in the break before the precedent session.

Poster in the poster exhibitionFormat AO portrait : 85 cm width x 120 cm high.Poster set-up : until Wed 2.9.20 at 11.00Material will be at disposal.

Posterflash PresentationsIn addition to the poster in the poster exhibition, some of the posters have been selected for a short oral presentation (5mn including Discussion, max 3 slides) in the posterflashes SSI-SSHH session onJoint session 2 : Thursday, September 3, 2020, 16.15-17.45Language : English (German or French)

Posterwalk SSI-SSHHOn Thursday September 3, 2020, 12.30-13.15Language : English (German or French)Please, wear a mask during the posterwalk

Oral presentationsSome of the submitted abstracts have been selected for an oral presentation, according to the scientific program.

Abstract publicationAbstracts are available in the abstract book, distributed onsite.

Awards SSI / SAFE-IDThe Swiss Society for Infectious Diseases (SSI) and the Swiss Academic Foundation for Education in Infectious Diseases (SAFE-ID) will award 2 prizes each in the amount of CHF 15 000.00 for outstanding scientific Achievements in basic research and in clinical research in infectious Diseases during the 2020 annual meeting.Award ceremony : Thursday, September 3, 2020-17.50-18.20

Awards SSHH– Best poster– Best project (innovation/implementation)– Best paperAward ceremony : Thursday, September 3, 2020-17.50-18.20

Registrationonline on www.meeting-com.ch / Conferences & Meetings or to the Congress Office Management as below

Meeting.com Sàrl Congress OrganisationRue des Pâquis 1 • PO box 100 CH-1033 Cheseaux-sur-LausanneT +41 (0)21 312 92 61 • F +41 (0)21 312 92 [email protected]

LocationPalexpo Congress Centre, www.palexpo.chRoute François-Peyrot 30, 1218 Le Grand-Saconnex, GenevaHall 1 and Hall 3

Registration fee Early fee Late fee & onsite (before August 12, 2020) (as of August 13, 2020)Member SSI-SSHH * CHF 270.00 CHF 390.00Non-Member CHF 350.00 CHF 480.00PhD Student ** CHF 100.00 CHF 130.00Nurses/Pflege/Soignant·e·s CHF 110.00 CHF 160.00

Registration for daily participation only onsite at the 50 % of late fee.

* In order to benefit from the Member fee, the annual membership 2020 has to be duly paid to the society.

** In order to benefit from the reduced fee, PhD students are required to send a document confirming their

status to the Congress Management by fax or scanned within 7 days from the date of registration.

Gen

eral

info

rmat

ion

Gen

eral

info

rmat

ion

8 9

AccommodationThe 2 following hotels can offer special prices for the participants of the congress :– Ibis Budget* Geneva Palexpo– Ibis Styles*** Geneva PalexpoRoute François-Peyrot 28, 1218 Le Grand Saconnex

For other hotels, please contact Geneva Tourism onhttps://www.geneve.com/en/

Networking EventsDue to the COVID-19, there will be no networking events during the joint meeting.

Location map

Language of the joint meetingThe offi cial congress language is English

SSI Sessions Presentations & slides in English

Keynotes & Presentations & slides in German or FrenchSSI-SSHH Joint sessions & Simultaneous translation German <-> FrenchSSHH Sessions

Simultaneous translation Simultaneous translation German <-> French will be provided on Wednesday September 2 and on Thursday September 3, 2020 for several SSHH relevant sessions which are marked accordingly in the program

Shorts talks, English (German or French)Posterfl ashes, Posters

Rooms used

SSI Room C (Hall 1) Rooms X & V & W (Hall 3)

SSHH Room C (Hall 1)

Keynotes Room C (Hall 1)

Joint sessions SSI-SSHH Room C (Hall 1)

Exclusive Symposium Room C (Hall 1)

Credits on demand toSwiss Society for Infectious Diseases (SSI)

Gen

eral

info

rmat

ion

Gen

eral

info

rmat

ion

C

B

A

12

4

6

75

3

AUTOROUTEMOTORWAYAUTOBAHN

ROUTEROADSTRASSE

ACCÈS PARKINGCAR PARK ACCESSPARKHAUSZUFAHRT

AÉROPORT INTERNATIONAL DE GENÈVEGENEVA INTERNATIONAL AIRPORTINTERNATIONALER FLUGHAFEN GENF

GARE CFF GENÈVE-AÉROPORTGENEVA-AIRPORT TRAIN STATIONBAHNHOF GENF-FLUGHAFEN

ACCÈS PIÉTONSPEDESTRIAN ACCESSFUSSGÄNGERZUGANG

ACCÈS MARCHANDISESGOODS ACCESSWARENZUFUHR

ENTRÉES VISITEURSVISITORS ENTRANCESBESUCHER-EINGANG

No 5

No 5 & 28

Voie-des-Traz

rout

e de

Fer

ney

impasse Colombelle

rue Jo-Siffert

chemin Edouard Sarasin

route François-Peyrot

chem

in d

es P

réjin

s

PARCSARASIN

AD

MIN

ISTR

ATIO

N

VILLASARASIN

route François-Peyrot

STARLINGHÔTEL

route des Batailleux

PLAN DE SITUATIONSITUATION MAP

LAGEPLAN

LÉGENDE - LEGEND - LEGENDE

SORTIE GAREAÉROPORT

No 5 & 28

No 28

GU

ÉRIT

EP

RIN

CIP

ALE

GU

ÉRIT

EA

DM

INIS

TRAT

ION

GU

ÉRIT

EM

AR

CH

AN

DIS

E

RAMPE P49

HÔ

TEL

IBIS

55

LAUSANNE / BERNE / ZURICH

LYON / PARIS / GENÈVE

HALLE DE FRÊT

HALLE 1

HALLE 2

HALLE 4

HALLE 5

HALLE 6

HALLE 7ARENA729 721

719

61

7

61

8

61

9

620

622

615

614

62

3

624

708

54

601

41

48

51

58

44

45

24

31

21

28

E13

25

14

15

E6

11

606

AÉROPORT INTERNAT.DE GENÈVE

No 28

CENTREDE

CONGRÈS

GARE CFF

18

E7

HALLE3

61

66

13

513

10 11

Join

t mee

ting

orga

niza

tion

Swiss Society for Infectious Diseases SSICongress OrganizationProf. Nicolas Müller, University Hospital of ZurichPresident SSI and Congress President

SSI governing boardPresident Nicolas Müller (Zurich)

Treasurer Stephen Leib (Bern)

Members Manuel Battegay (Basel), Christoph Berger (Zurich), Pierre-Yves Bochud (Lausanne), Thierry Calandra (Lausanne), Hansjakob Furrer (Bern), Barbara Hasse (Zurich), Laurent Kaiser (Geneva), Claude Scheidegger (Basel), Madeleine Rothen (Basel), Christian van Delden (Geneva), Pietro Vernazza (St.Gallen), Rainer Weber (Zurich), Andreas Widmer (Basel)

Scientific committeeBarbara Hasse (Zurich), Nina Khanna (Basel), Gilles Wandeler (Bern), Werner Albrich (St. Gallen), Benoît Guery (Lausanne), Christian van Delden (Geneva)

SSI Clinical Health SessionJan Fehr (Zurich), Claude Scheidegger (Basel), Barbara Hasse (Zurich)

Swiss Society for Hospital Hygiene SSHHCongress OrganizationDr med. Matthias Schlegel, Kantonsspital St.GallenPresident SSHH and Congress President

SSHH boardPresident Matthias Schlegel (St.Gallen)

Past President Gerhard Eich (Zurich)

Treasurer Catherine Plüss-Suard (Bern)

Members Marc Dangel (Basel), Pierre Deriaz (Neuchâtel), Felix Fleisch (Chur), Stefan Kuster (Zurich), Marie-Theres Meier (Zurich), Walter Zingg (Geneva)

Scientific committeePosters & ProjectsFelix Fleisch (Chur), Marie-Theres Meier (Zurich), Walter Zingg (Geneva)

Pro

gram

at a

gla

nce

– W

edne

sday

, Sep

tem

ber 2

09.00 Registration & welcome FOYER

10.00-11.30

SSHH Symposium 1 Das neue Spital – Hygienisch perfekt ROOM C

11.30-12.00 Coffee break & Poster viewing EXHIBITION & POSTERS

12.00-13.15

SSHH Symposium 2 Rollenwechsel : von Auditieren zu Auditierten ROOM C

13.15-14.15 Lunch break & Poster viewing EXHIBITION & POSTERS

14.15-15.45

SSHH Symposium 3 Prevention of SARS-CoV2-in the hospital ROOM C

SSI Postgraduate Course ROOMS V & W


16.15-17.45

SSHH Symposium 4 Innovation / Implementation ROOM C


17.45-18.00 Short break EXHIBITION & POSTERS

18.00-19.00

SSHH GENERAL ASSEMBLY ROOM C

12 13

Pro

gram

at a

gla

nce

– Th

ursd

ay, S

epte

mbe

r 308.00 Registration & welcome FOYER

09.15 Welcome address ROOM C

09.30-10.00 Keynote 1 ROOM C

Stefan Kuster, BAG, Bern

10.00-10.30 Keynote 2 ROOM C

Marcel Salathé, Lausanne


11.00-12.30

Joint Session 1 ROOM C

Clinical public health with public health flashes

12.30-14.15 Lunch break EXHIBITION & POSTERS

SSI POSTERWALK / SSHH GUIDED POSTERWALK

14.15-15.45

SSHH Session ROOM C

Strategie NOSO – von der Strategie zur Umsetzung

SSI Session 1 ROOM W

NRP72 and antimicrobial resistance

SSI Session 2 ROOM V

C. Difficile epidemiology and therapy clostridioides difficile

SSI Session 3 ROOM X

HIV Hepatitis


16.15-17.45


Posterflashes SSI / SSHH

17.50-18.20 SSI-SSHH Awards ROOM C

18.20-19.00 SSI General Assembly ROOM C

Pro

gram

at a

gla

nce

– Fr

iday

, Sep

tem

ber 4

07.30 Registration & welcome FOYER

08.30-10.00


Pneumonia from microbiome to clinics


10.30-12.00

SSI Session 4 ROOM C

Personalized medicine for infections – translational aspects/transplantation


Pediatric infectious diseases group Switzerland (PIGS) Symposium


12.45-13.45 SCIENTIFIC SYMPOSIUM – ViiV HEALTHCARE ROOM C

13.45-15.15


Antimicrobial/antifungal stewardship


Personnalized medicine for infections – virology / specialized population


15.45-16.45


SSI Diagnostic quiz

16.45 Closing remarks and end of the Joint meeting

14 15

POWER REIMAGINEDAN INNOVATIVE NEW TREATMENT FOR YOUR PATIENTS LIVING WITH HIV

Brief Product InformationDovato film coated tabletsAI: Dolutegravir 50 mg, lamivudine 300 mg. I: For the therapy of HIV infection in adults and adolescents (from 12 years of age; weighing at least 40 kg) without pre-treatment or as a replacement for a current antiretroviral therapy in patients who have been virologically suppressed with stable antiretroviral therapy for at least six months without a history of virological failure and no HIV-1 resistance mutations to the INI or NRTI class. D: one tablet once daily (with or without food). Dovato is a fixed-dose tablet and should not be prescribed to patients requiring dose adjustments (e.g. with a creatinine clearance below 50 ml/min). CI: Hypersensitivity to the active ingredients or to any of the excipients. Co-administration with dofetilide or pilsicainide. Dovato should not be used concomitantly with high doses of co-trimoxazole. W/P: Hypersensitivity reactions: Discontinue Dovato and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop. Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Monitoring for hepatotoxicity is recommended. A dose adjustment of metformin should be considered when starting and stopping coadministration of Dovato with metformin. IA: Dovato should not be used with any other drugs containing dolutegravir, lamivudine or emtricitabine, except when an extra dolutegravir 50mg dose is required due to DDIs. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, carbamazepine, etravirine (without boosted protease inhibitors), efavirenz, nevirapine or tipranavir/ritonavir. Avoid co-administration with oxcarbazepine, phenytoin, phenobarbital or St. John’s wort. Administer dolutegravir 2 hours before or 6 hours after antacids containing polyvalent cations or supplements containing calcium or iron. Avoid co-administration with sorbitol-containing medicines. P/L: Do not use in in women planning to become pregnant. In women of child bearing potential a pregnancy test should be performed and pregnancy should be excluded before starting Dovato. Women of child bearing potential should be advised to use effective contraception throughout treatment. If a woman becomes pregnant while taking Dovato and the pregnancy is confirmed in the first trimester, it is recommended to switch to an alternative regimen. Dovato should be used during the rest of the pregnancy only if the expected benefit justifies the potential risk to the foetus. Avoid breast-feeding. AE: Very common: Headache, nausea, diarrhoea. Common: suicidal ideation, depression, anxiety, insomnia, abnormal dreams, dizziness, somnolence, vomiting, flatulence, abdominal pain, upper addominal pain, abdominal discomfort, rash, pruritus, fatigue, malaise, fever. Uncommon: neutropenia, anaemia, thrombocytopenia, hypersensitivity, immune reconstitution syndrome, suicide attempt, disturbances in attention, hypoaesthesia, gastroesophageal reflux disease, hepatitis, transient rises in liver enzymes. Post-marketing experience: Common: hyperlactataemia, alopecia, arthralgia, myalgia. Uncommon: weight increased. Rare:lactic acidosis, pancreatitis, acute hepatic failure, rhabdomyolysis. Very rare: paraesthesia, peripheral neuropathy, pure red cell aplasia. Sales category: A. Date of information: April 2020. ViiV Healthcare GmbH. For more detailed information see www.swissmedicinfo.ch. To report adverse drug events please contact [email protected].

ViiV Healthcare GmbH, Talstrasse 3-5, 3053 Münchenbuchsee

PM-C

H-D

LL-A

DVT

-200

004-

06/2

020

POWERFUL, DURABLE EFFICACY2,3

HIGH BARRIER TO RESISTANCE2,3

TDF, TAF AND ABC FREE1

Dovato is indicated for the therapy of HIV infection in adults and adolescents (from 12 years of age; weighing at least 40 kg) without pre-treatment or as a replace-ment for a current antiretroviral therapy in patients who have been virologically suppressed with stable antiretroviral therapy for at least six months without a history of virological failure and no HIV-1 resistance mutations to the INI or NRTI class.1

Tolerability:In the GEMINI studies (treatment-naïve patients) adverse event (AE) profiles at 96 weeks were comparable across both arms of the study with significantly lower rate of drug-related AEs for DTG + 3TC vs. DTG + TDF/FTC. The most common drug-related AE was headache (1 % in both arms), drug-related AEs leading to withdrawal from the study occurred in 2 % in both arms.2 In the TANGO study (virologically suppressed patients) drug-related AEs and AEs leading to withdrawal from the study at week 48 occurred more frequently with DTG/3TC as compared with a TAF containing regimen (12.2 % vs. 1.3 % and 3.5 % vs. 0.5 %). The most common drug-related AEs in the DTG/3TC study arm was insomnia (1.1 % vs. 0 % with a TAF-containing regimen).3

References:1. Dovato Swiss Prescribing Information, www.swissmedicinfo.ch. 2. Cahn P, Madero JS, Arribas JR, et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naïve Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2020;83(3):310-318. 3. Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Rando-mized, Non-inferiority TANGO Study. Clin Infect Dis 2020. doi: 10.1093/cid/ciz1243.

16 17

09.00 Registration & welcome coffee WELCOME DESK/EXHIBITION SPACE

10.00-11.30

SSHH SYMPOSIUM 1 ROOM C

Das neue Spital – Hygienisch perfekt Chairs : Marc Dangel, Basel ; Felix Fleisch, Chur

10.00-10.30 Sind soziotechnische Systeme (Spitäler) designbar ?Hugo Sax, Zurich

10.30-11.00 White Paper : Welche Anforderungen sind für das zukünftige Spital gefordet ?Carlo Colombo, Zurich

11.00-11.30 Nouvel hôpital –> zéro infection : utopie ou réalité ?Pascal Forestier, Rennaz ; Cristina Bellini, Rennaz

11.30-12.00 Coffee break & poster viewing EXHIBITION & POSTERS

12.00-13.15


Rollenwechsel : von Auditieren zu Auditierten Chairs : Marie-Theres Meier, Zürich ; Catherine Plüss-Suard, Bern

12.00-12.25 Peer ReviewsIsabelle Praplan, Bern

12.25-12.50 Audit im Operationssaal : Durchführung und ResultateBarbara Ligresti, Basel

12.50-13.15 Inspection du retraitement des endoscopes Swissmedic Retour d’expérience préparatif aux HUGDelphine Perréard, Geneva


Pro

gram

Wed

nesd

ay, S

epte

mbe

r 214.15-15.45


Prevention of SARS-CoV2-in the hospital Chairs : Matthias Schlegel, St.Gallen ; Isabelle Koenig, Lausanne

14.15-14.35 Aerosole und der Umgang mit Masken im SpitalChristoph Fux, Aarau

14.35-14.55 Infections nosocomiales à Covid-19 : résultats de la surveillance hospitalière CH-SURCéline Gardiol, BAG, Bern

14.55-15.25 La Covid-19 : un défi pour les établissements médico-sociaux (EMS)Agathe Deschamps, Neuchâtel ; tbd

15.25-15.45 « Wir schalten das dann auf… » – Umgang mit COVID-19 aus Organisations- und ManagementsichtHarald Tuckermann, St. Gallen


Chairs : Nicolas Müller, Zurich ; Christian van Delden, Geneva

15.45-16.15 Coffee break & poster viewing EXHIBITION & POSTERSPro

gram

Wed

nesd

ay, S

epte

mbe

r 2

18 19

16.15-17.45


Innovation / Implementation Chairs : Walter Zingg, Geneva ; Stefan Kuster, Bern

16.15-16.25Short talk S-01

Les précautions standard autrementPierre Deriaz, Neuchâtel

16.25-16.35Short talk S-02

Spatiotemporal COVID-19 surveillance of hospital employees using an online symptom reporting platform with instant automated analysisPhilipp Kohler, St.Gallen

16.35-16.45Short talk S-03

To whom it may concern: Identifikation von Stakeholdergruppen durch die Methode der formativen EvaluationMirjam Faes Hesse, Zurich

16.45-16.55Short talk S-04

Health Care Workers’ Seasonal Influenza Vaccination Campaign Perception – Potential Negative Impact of Compulsory Personal Protection Obligations on Vaccine UptakeTiziana Canzoniere Orlandi, Olten

16.55-17.05Short talk S-05

Aufbau einer automatischen VAE-Surveillance an einem Schweizerischen UniversitätsspitalOliver Wolffers, Bern

17.05-17.15Short talk S-06

Termination of a multidrug resistant Pseudomonas aeruginosa outbreak on intensive-care units by implementation of ‘water-free’ patient-care and sinkVerena Schärer, Zurich

17.15-17.30 Wie gewinne ich einen SGSH-Preis ? Von der Idee zur EingabeHugo Sax, Zurich

17.30-17.45 J’ai gagné un prix – comment j’ai fait ?Pierre Deriaz, Neuchâtel


Chairs : Nicolas Müller, Zurich ; Christian van Delden, Geneva

17.45-18.00 Short break EXHIBITION & POSTERS

18.00-18.45 SSHH GENERAL ASSEMBLY ROOM C

Pro

gram

Wed

nesd

ay, S

epte

mbe

r 208.00 Registration WELCOME DESK

09.15 Welcome address ROOM C

Nicolas Müller, Zurich ; Matthias Schlegel, St.Gallen

09.30-10.30

Keynote 1 ROOM C

Chair : Matthias Schlegel, St.Gallen

09.30-10.00 COVID-19 – a public health perspective Stefan Kuster, BAG, Bern

Keynote 2 ROOM C

Chair : Nicolas Müller, Zurich

10.00-10.30 Digitalisierung in der COVID-19 Pandemie Marcel Salathé, Lausanne


11.00-12.30

SSI / SSHH JOINT SESSION 1 ROOM C

Clinical public health with public health flashes Chairs : Jan Fehr, Zurich ; Claude Scheidegger, Basel

11.00-11.20 COVID-19 treatment : present and future challengesLaurent Kaiser, Geneva

11.20-11.40 Corona Immunitas : population-based estimation of SARS-CoV-2 seroprevalence in SwitzerlandMurielle Bochud Lausanne

11.40-12.00 Zwischen Wissenschaft und Politik während der ersten Covid-19-Welle in der SchweizManuel Battegay, USB Basel

12.15-12.30 DiscussionAll speakers


SSI Posterwalk / SSHH guided Posterwalk

Pro

gram

Thu

rsda

y, S

epte

mbe

r 3

20 21

14.15-15.45

SSHH SESSION ROOM C

Strategie NOSO – von der Strategie zur Umsetzung Chairs : Gerhard Eich, Zurich ; Pierre Deriaz, Neuchâtel

14.15-14.45 Surveillance : Chancen und LimitenWalter Zingg, Geneva

14.45-15.15 Sicht des BAG, Angebote SwissnosoVirginie Masserey, BAG, Bern ; Rami Sommerstein, Luzern

15.15-15.45 Epi-Radar in der Schweiz : VRE, Candida auris und andereDanielle Vuichard Gysin, Swissnoso, Bern

SSI SESSION 1 ROOM W

NRP72 and antimicrobial resistanceChairs : Silvio Brugger, Zurich ; Adrian Egli, Basel

14.15-14.45 NRP72 und antimikrobielle ResistenzSarah Tschudin Sutter, Basel

14.45-15.15 Surveillance of antibiotic resistance development in SwitzerlandAdrian Egli, Basel

15.15-15.30Short talk S-07

Healthcare-associated infections, antibiotic use and resistance in Swiss long-term care facilities: a multicentre point-prevalence studyPhilipp Kohler, St.Gallen

15.30-15.45Short talk S-08

Antibacterial prescribing in the outpatient setting: results from a longitudinal survey and a sentinel network of physicians, Switzerland, 2018Catherine Plüss Suard, Bern

SSI SESSION 2 ROOM V

C. Difficile epidemiology and therapy clostridioides difficileChairs : Christoph Fux, Aarau ; Yvonne Achermann, Zurich

14.15-14.45 C. difficile : How to diagnose _ How to treatFrédéric Barbut, Paris (F)

14.45-15.15 Treatment of C. difficileBenoît Guery, Lausanne

15.15-15.30Short talk S-09

Epidemiology and outcomes of Clostridioides difficile infections among allogeneic hematopoietic stem cell transplant recipients in Switzerland, 2009-2019Silvio Ragozzino, Basel

15.30-15.45Short talk S-10

Impact of immunosuppression on Clostridioides difficile infectionEleftheria Kampouri, Lausanne

Pro

gram

Thu

rsda

y, S

epte

mbe

r 314.15-15.45

SSI SESSION 3 ROOM X

HIV HepatitisChairs : Katharine Darling, Lausanne ; Gilles Wandeler, Bern

14.15-14.45 Long-acting antiretroviral therapy in 2020 : challenges and opportunitiesChloe Orkin, London (GB)

14.45-15.15 Hepatocellular carcinoma surveillance in patients treated for viral hepatitis : who should we screen ?Jean-François Dufour, Bern

15.15-15.30Short talk S-11

Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection : a randomized, controlled, multi-site, non- inferiority trialDominique Laurent Braun, Zurich

15.30-15.45Short talk S-12

Diagnosis of latent tuberculosis infection is associated with re-duced HIV viral load and lower risk for opportunistic infections in people living with HIVKatharina Kusejko, Zurich


16.15-17.45


Posterflashes SSI / SSHHChairs : Enos Bernasconi, Lugano ; Nicolas Müller, Zurich

16.15-16.20P01* / SSI

Trained immunity confers broad-spectrum protection against bacterial infectionsEleonora Carlo, Lausanne

16.20-16.25P02* / SSI

Evaluation of Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neuronal Damage in Experimental Pneumococcal MeningitisNgoc Dung Le, Bern

16.25-16.30P03* / SSHH

Does employee turnover matter for central line-associated blood-stream infections ?Peter W. Schreiber, Zurich

16.30-16.35P04* / SSI

Epidemiology of Candidemia in Swiss Tertiary Care Hospitals : a 15-Year Study 2004 to 2018Kai-Manuel Adam, Basel

Pro

gram

Thu

rsda

y, S

epte

mbe

r 3

22 23

16.35-16.40P05* / SSI

Drug therapy decisions for COVID-19 during the pandemic in Switzerland : a national multicenter panel surveyMichèle Birrer, Bern

16.40-16.45P06* / SSHH

Prevalence of SARS-CoV-2 Antibodies among Swiss Healthcare Workers - Results of a Prospective Cohort StudyChristian R. Kahlert, St.Gallen

16.45-16.50P07* / SSI

Lung ultrasonography for risk stratification in patients with COVID-19 : a prospective observational cohort studyThomas Brahier, Lausanne

16.50-16.55P08* / SSI

Bacterial Pneumonia in HIV-infected individuals in the Swiss HIV Cohort Study (SHCS) : Incidence and Risk factorsSuraj Balakrishna, Zurich

16.55-17.00P09* / SSHH

How many asymptomatic SARS-CoV-2 infected patients are being missed among hospitalized patients ? – Results of a prospective universal admission screeningThomas Scheier, Zurich

17.00-17.05P10* / SSI

Surgical strategy has a higher impact than adding rifampin to anti-biotic regimen of Cutibacterium spp. periprosthetic joint infectionKatharina Kusejko, Zurich

17.05-17.10P11* / SSI

Epidemiology and management of pneumonia based on data entry in a computerised decision support system for antimicrobial prescriptions: a retrospective studyGaud Catho, Geneva

17.10-17.15P12* / SSHH

When cold water is too warm : Health-care associated legionnaire’s disease associated with hot seasonWerner Albrich, St.Gallen

17.15-17.20P13* / SSI

Covid-19 risk stratification algorithms based on soluble trigger-ing receptor expressed on myeloid cells and interleukin-6 in the emergency department of a swiss hospitalMathias Van Singer, Lausanne

17.20-17.25P14* / SSI

Determinants of non-alcoholic fatty liver disease in a single center of the Swiss HIV Cohort StudyCarlotta Ribensahm, Bern

17.25-17.30P15* / SSHH

Successful reduction of urinary catheter days and (in)adequate catheterization after introduction of a prevention bundleMichela Cipriani, St.Gallen

17.30-17.35P16* / SSI

Epidemiology and outcomes of microbiologically documented bacterial foodborne infections in solid organ transplant recipients: a 10-year nationwide cohortLorena van den Bogaart, Lausanne

Pro

gram

Thu

rsda

y, S

epte

mbe

r 317.35-17.40P17* / SSI

Quantifying the heterogeneity of the MSM population in the SHCS: Behavioural clusters predict sexual behaviour and syphilis cases in MSMSara Andresen, Zurich

17.40-17.45P18* / SSHH

COVID-19 infections amongst healthcare workers: Epidemiology, potential modesof transmission and cluster analysesMartin Purtak, Aarau

* ALSO PRESENTED AS POSTER

17.50-18.20 SSI-SSHH Awards ROOM C

18.20-19.00 SSI General assembly ROOM C

Pro

gram

Thu

rsda

y, S

epte

mbe

r 3

24 25

08.00 Registration WELCOME DESK

08.30-10.00


Pneumonia from microbiome to clinicsChairs : Noémie Boillat Blanco, Lausanne ; Werner Albrich, St. Gallen

08.30-09.00 Respiratory microbiome in health and diseases : from bench to clinicMarkus Hilty, Bern

09.00-09.30 The utilization of rapid tests and its impact on antimicrobial stewardshipNoémie Boillat Blanco, Lausanne

09.30-10.00 Where there are no guidelines : the complicated pneumonia patientMartin Kolditz, Dresden (DE)


10.30-12.00

SSI SESSION 4 ROOM C

Personalized medicine for infections – translational aspects/transplantationChairs : Nicolas Müller, Zurich ; Christian van Delden, Geneva

10.30-11.00 Personalized medicine for invasive fungal diseasePierre-Yves Bochud, Lausanne

11.00-11.30 Personalized medicine for bone and joint infectionTristan Ferry, Lyon (FR)

11.30-11.45Short talk S-13

Probability of target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection : a prospective cohort study of unbound plasma concentrations and individual MICsNicolas Gürtler, Basel

11.45-12.00Short talk S-14

Systematic screening of viral and human genetic variation in the Swiss HIV Cohort study : indicates link between antiretroviral resistance and immune escapeHuyen Nguyen, Zurich

Pro

gram

Frid

ay, S

epte

mbe

r 410.30-12.00


Pediatric infectious diseases group Switzerland (PIGS) SymposiumChairs : Klara Posfay-Barbe, Geneva ; Ulrich Heininger, Basel

10.30-11.00 EBV infection in children : from kissing disease to PTLDArnaud L’Huillier, Geneva

11.00-11.30 How long is a piece of string : Optimal duration of antibiotic therapyJulia Bielicki, Basel

11.30-12.00 Beyond guidelines – opportunities and challenges in improving paediatric sepsisLuregn Schlapbach, Zurich


12.45-13.45

SCIENTIFIC SYMPOSIUM ViiV HEALTHCARE ROOM C

New directions in HIV medicineChair : Barbara Hasse, Zurich ; Enos Bernasconi, Lugano

12.45-12.50 Welcome

12.50-13.10 HIV and Ageing - Planning for a Healthy Future Tristan Barber, London

13.10-13.30 State of the ART - Highlights from 2020 Chloe Orkin, London

13.30-13.45 Q & A Session

13.45-15.15


Antimicrobial/antifungal stewardshipChairs : Nina Khanna, Basel ; Werner Albrich, St.Gallen

13.45-14.15 The role of outpatient parenteral antibiotic therapy (OPAT) for antimicrobial stewardshipMichael Osthoff, Basel

14.15-14.45 Antibiotic duration in Gram-negative bacteremia : long, short or individualized ? Data from the PIRATE projectAngela Huttner, Geneva

14.45-15.15 The utilization of rapid tests and its impact on antimicrobial stewardshipPeter Keller, Bern

Pro

gram

Frid

ay, S

epte

mbe

r 4

26 27

13.45-15.15


Personnalized medicine for infections – virology / specialized populationChairs : Luisa Salazar-Vizcaya ; Matthias Cavassini, Lausanne

13.45-14.15 Personalized medicine in HIV prevention and treatmentRoger Kouyos, Zurich

14.15-15.00 Mathematical modelling and Machine-learningKarsten Borgwardt, Zurich

15.00-15.15 Discussion


15.45-16.45


SSI Diagnostic quiz Chairs : Ursula Flückiger, Aarau

15.45-16.45 Diagnostic quiz

16.45 Closing remarks and End of the meeting ROOM C

Nicolas Müller, Zurich ; Matthias Schlegel, St.Gallen

Pro

gram

Frid

ay, S

epte

mbe

r 4

Spo

nsor

s

Kind thanks to our sponsors

Scientifi c symposiumFriday, September 4, 202012.45-13.45

Partner SSHH Symposium 2020

28

Spo

nsor

sKind thanks to our sponsors

Joint Meeting 2020 · In addition to the poster in the poster exhibition, some of the posters have...

Documents

Transcript of Joint Meeting 2020 · In addition to the poster in the poster exhibition, some of the posters have...